Icariside II, a novel phosphodiesterase-5 inhibitor, attenuates streptozotocin-induced cognitive deficits in rats
详细信息 查看全文
- 作者：Caixia Yin ; Yuanyuan Deng ; Jianmei Gao ; Xiaohui Li ; Yuangui Liu ; Qihai Gong ; gqh@zmc.edu.cn" class="auth_mail" title="E-mail the corresponding author
- 关键词：AD ; Alzheimer&rsquo ; s disease ; ANOVA ; analysis of variance ; APP ; beta-amyloid precursor protein ; Aβ ; beta-amyloid ; BACE1 ; beta-secretase 1 ; BCA ; bicinchoninic acid ; COX-2 ; cyclooxygenase-2 ; ELISA ; enzyme-linked immunosorbent assay ; ICS II ; icariside II ; ICV ; intracerebroventricular ; IDE ; insulin degrading enzyme ; IL-1β ; interleukin-1β ; IκB ; inhibitory κB ; NEP ; neprilysin ; NF-κB ; nuclear factor κB ; PDE5 ; phosphodiesterase-5 ; STZ ; streptozotocin ; TGF-β1 ; transforming growth factor-β1 ; TNF-α ; tumor
- 刊名：Neuroscience
- 出版年：2016
- 出版时间：22 July 2016
- 年：2016
- 卷：328
- 期：Complete
- 页码：69-79
- 全文大小：3202 K
文摘
- •
Icariside II ameliorated cognitive deficits and neuronal morphological damage.
- •
Icariside II reduced the level of PDE5 in STZ rat.
- •
Icariside II attenuated the level of Aβ in STZ rat by down-regulation of APP and BACE1 and up-regulation of NEP.
- •
Icariside II inhibited the overexpression of TNF-α, IL-1β, COX-2 and TGF-β1 induced by STZ.
- •
Icariside II prevented IκB-α degradation and NF-κB activation induced by STZ.